All News

Venture capital’s refusal to continue support helped Cyan Technology into liquidation. Rebuilt by its management, Cyan is now wary of asking VCs for money.

A politician's gaffe highlights the gender gap in science. Political action, not talk, is what's needed to close it.

Scientists are moving around as never before. And, argues Jean Guinet from the OECD, that’s not necessarily a bad thing.

Better, brighter, faster – that's where photonic lasers are trying to take us. A lay guide to the technology.

A British start-up is betting it has a better way for television networks to watch their viewers watching them.

With licensing and collaboration now the lifeblood of the drug industry, the annual BIO-Europe get-together was focused on partnering. Nuala Moran was there.

On the glut of patenting, BASF's rising research budget, football fever in the Commons, and other insights into R&D management

"Scientific work … must be done for itself, for the beauty of science." Marie Curie, chemist & physicist (1867 - 1934)

New regulations on the registration and testing of chemicals could have some problematic knock-on effects on European R&D – but they could also bring some lucrative work the way of contract research organisations.

Some strange new ways of raising money are starting to emerge - but would-be borrowers and lenders are still making sense of them.

The pace of forming academic spin-out companies picked up in the US in 2004 after a two-year slump, according to a survey released today.

Reports of incubators' demise were premature

After the initial hype, the long haul through clinical development and the inevitable pitfalls, gene therapy is on the verge of becoming a commercial reality in Europe - ahead of the US.